Dr. Maccecchini founded Annovis in May 2008 to develop better therapeutics for Alzheimer’s, Parkinson’s and other neurodegenerative diseases. She was partner and director of two angel groups, Robin Hood Ventures and MidAtlantic Angel Group. Additionally, Dr. Maccecchini was the founder and CEO of Symphony Pharmaceuticals/Annovis, a biotech company that was sold in 2001 to Transgenomic. She served as general manager of Bachem Bioscience, the US subsidiary of Bachem AG, Switzerland and Head Molecular Biology Mallinckrodt. Dr. Maccecchini did one postdoc at Caltech and one at the Roche Institute of Immunology;her PhD in biochemistry is from the Biocenter of Basel with a two-year visiting fellowship at The Rockefeller University.